-
GLP-1-RAs lower risk of death and cardiovascular events in people with type 2 diabetes and IMIDs
Scientists from Arthritis Research Canada found a significant drop in all-cause mortality and major adverse cardiovascular events in people from the group who took glucagon-like peptide-1 receptor agonists.